Please login to the form below

Not currently logged in
Email:
Password:

anaesthetics

This page shows the latest anaesthetics news and features for those working in and with pharma, biotech and healthcare.

Grünenthal buys Zomig rights as AZ slimming drive continues

Grünenthal buys Zomig rights as AZ slimming drive continues

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5 injectable pain / anaesthetic products.

  • Deal Watch September 2016 Deal Watch September 2016

    500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva, Nimbex, Tracrium, Mivacron and Anectinein – excludes US/CA rights].

  • Deal Watch June 2016 Deal Watch June 2016

    Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

  • Pharma deals in June 2015 Pharma deals in June 2015

    Neosaxitoxin, novel anaesthetic for local anaesthesia and post-op pain management. Collaboration, licence.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Baxter's medical products business has annual sales of over $9bn and a portfolio of intravenous solutions and nutritional therapies, drug delivery systems, premixed and other injectable drugs, inhalation anaesthetics and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting (OAC) is the market access agency within OPEN Health. We are value communications experts and we specialise...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics